Obese children as young as six could benefit from weight-loss jabs
Researchers may suggest that obese children under the age of six can benefit from getting weight loss jabs.
According to the figures of the Department of Health and Social Care, approximately one -third of children who leave primary school at the age of 11 live with overweight or obesity, and then put them at the risk of diabetes, stroke and some cancers in life.
Although there are a number of weight loss jabs in the UK NHS, it is recommended for adults for the treatment of DA-KLO or Type 2 diabetes. In the United States, weight loss was approved for Jab Wegovy, 12 to 17 years of obesity.
A PUBLISHED US WORK Jama Paediatrics Wegovy and Mounjaro suggest that weight loss jabs can help children under the age of six years with obesity and type 2 diabetes.
However, the researchers found that stomach problems were “significantly more common” among young people who took medications.
Approximately 1.5 million people in the UK are receiving drugs such as Mounjaro, Özempic and Wegovy to deal with conditions such as obesity and diabetes.
Drugs known as GLP-1 agonists treat diabetes mainly, but are also available in NHS or through special providers to help adults with high body mass index.
Drugs are mainly used to control blood sugar levels, but reduce food requests and as a result can cause rapid weight loss.
Experts in the United States, young people aged six to 17 GLP-1 agonists containing 18 trials and meta-analysis carried out a study.
In general, the studies included 1,402 children and compared the effectiveness of GLP-1 agonists in obese, overweight young people with placebo treatment.
Researchers found that drugs such as blood sugar control and weight in obese children and those with type 2 diabetes “significantly healed”.
However, they emphasized that “gastrointestinal adverse events”, including nausea, vomiting, diarrhea and constipation, they were “significant more common” among people who take medications.
Researchers in the magazine, longer follow-up times in future trials and more real world work “children and adolescents need to determine the long-term effects of GLP-1 drugs,” he added.
The latest data published by NHS, in the UK 6th year (10 to 11 years) children 22.1 percent of children in 2023-2024 obese, 2022-2023’te 22.7 percent fell.
Although a third year has fallen in a row, the figure is still higher than the previous years.
Other places, the National Children’s Measurement Program, which had one of the 10 children participating in the primary school in the UK, was obese in 2022-2023 from 9.2 percent to 2023-2024.
Naved Sattar, a professor of cardiometabolic medicine at the University of Glasgow, said: ız We need more security assessment for new drugs, including effects on growth and puberty, and we should consider how much such drugs are needed.
